News | July 27, 2021
Biocon Biologics partners Adagio to manufacture antibody for COVID-19
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
ADG20, a novel monoclonal antibody targeting the spike protein of SARS-CoV-2 and related coronaviruses
The first quarter performance reflects growth across all its business divisions as the company continued to operate at normal levels
The companies anticipate clinical studies to begin in August, subject to regulatory approvals
Osimertinib works by slowing or stopping the growth of cancer cells and binds to a certain protein (epidermal growth factor receptor-EGFR) in some tumors
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
Cocktails of 2 mAbs based products are better equipped to deal with variants than single mAb based products which have a tendency of losing their efficacy with rapidly generating variants
BALflu is approved by DCGI for emergency use for the treatment of COVID-19
Nanoform and Celanese intend to work on formulation development, leveraging each organization's unique formulation expertise.
Targeted production of the dual vector Sputnik V for the first 12 months is 50 million doses from the date of start of commercial production
The DREAM-ND Phase III trial has now enrolled 588 CKD patients not-on-dialysis.
Subscribe To Our Newsletter & Stay Updated
